TICKERNERD
Menu
SENSSENSHealthcare · Medical Devices

SENS Stock Forecast: Senseonics Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$9.02
−1.53% on the day

The 8 Wall Street analysts covering Senseonics Holdings, Inc. hold a median 12-month price target of $15 — +60.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$476.9M
Ticker Nerd rank
31 / 100
Median analyst target
$15
Analysts covering
8
Revenue$14.5M+117.8% y/y
Operating income−$36.0M
Net income−$36.7M
Free cash flow−$30.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−3.3%
YTD
+63.4%
1Y
−2.4%
From 52W high
−12.8%
From 52W low
+85.6%
$5
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SENS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Senseonics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
78
Size
54
Momentum
51
Accruals
50
Growth
41
Quality
36
Value
26
Volatility
26
Issuance
9

Revisions (78): Analysts have, on balance, been raising their forecasts.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SENS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SENS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26SENSHigh $18Median $15Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
4 Buy3 Hold1 Sell
Low $8Median $15High $18

The green dot is the last close — the median target sits +60.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsOutperform—
12 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026StifelMaintainsHold—
6 Nov 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025BarclaysMaintainsOverweight—
5 Nov 2025TD CowenMaintainsBuy—
27 Aug 2025BarclaysInitiatesOverweight—
15 July 2025TD CowenInitiatesBuy—
8 July 2025HC Wainwright & Co.MaintainsBuy—
10 Apr 2025MizuhoInitiatesOutperform—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.MaintainsBuy—
19 July 2023JefferiesInitiatesUnderperform—
11 May 2023HC Wainwright & Co.ReiteratesBuy—
25 July 2022HC Wainwright & Co.MaintainsBuy—
19 Aug 2021HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SENS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SENS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Senseonics Holdings, Inc. returned −2.4% against +16.2% for the S&P 500, dividends included.

SENS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26SENSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SENS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Senseonics Holdings, Inc. (SENS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.4×

Cheaper than 91% of US stocks

Price / sales
9.8×

Cheaper than 14% of US stocks

Price / book
5.3×

Cheaper than 19% of US stocks

EV / EBITDA
−3.8×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
117.8%

Higher than 94% of US stocks

Earnings growth (YoY)
—
Gross margin
59.1%

Higher than 73% of US stocks

Operating margin
−248.5%

Higher than 10% of US stocks

Net margin
−225.3%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−118.2%

Higher than 12% of US stocks

Return on assets
−41.4%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Senseonics Holdings, Inc. (SENS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Senseonics Holdings, Inc. has a market value of $476.9M and an enterprise value of $404.5M.

  • Revenue in the twelve months to 30 June 2026: $48.5M. The latest quarter grew 117.8% year on year.

  • Net income over the same four quarters: −$109.4M, a −225.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$96.8M, after $886K of capital spending.

  • Shares outstanding: 52.9M.

  • Trailing P/E: −5.4×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Senseonics Holdings, Inc. employs 130 people — $373K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

SENS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SENSSenseonics Holdings, Inc.$476.9M
31
MASS908 Devices, Inc.$473.9M
86
SGHTSight Sciences, Inc.$457.4M
90
TCMDTactile Systems Technology, Inc.$498.9M
98
CERSCerus Corp.$438.0M
91
SSIISS Innovations International, Inc.$509.2M
22
DCTHDelcath Systems, Inc.$519.2M
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Senseonics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SENS news & analysis

Senseonics: Eversense 365 Adoption Has To Earn The Valuation

Seeking Alpha · 8 Oct 2026neutral

Seeking Alpha rates Senseonics Hold, citing sales growth, improving margins and Eversense 365’s product differentiation alongside adoption and funding risks. Recurring revenue depends on repeat implantations and wider prescriber uptake and insurance approval; high SG&A, dilution and negative free cash flow remain concerns.

Why it matters — SENS watchers may weigh recent growth and margin improvement against the execution and financing challenges that could affect Eversense 365 adoption.

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

Zacks Investment Research · 29 Sept 2026positive

Beta Bionics (BBNX) shares fell despite announcing a partnership integrating Senseonics' Eversense 365 continuous glucose monitor with its iLet automated insulin delivery system. The deal is expected to broaden CGM choice and strengthen BBNX's automated insulin delivery ecosystem across iLet and the upcoming Mint system.

Why it matters — The integration expands the commercial reach of Senseonics' Eversense 365 into automated insulin delivery platforms, potentially broadening its adoption among diabetes patients.

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

GlobeNewsWire · 14 Sept 2026positive

Senseonics announced a strategic partnership with Beta Bionics to integrate its Eversense 365 continuous glucose monitoring system with the iLet Bionic Pancreas automated insulin delivery system, with a commercial launch of the integrated system planned for Q4 2026. The partnership aims to pair year-long CGM with automated insulin delivery to simplify diabetes management.

Why it matters — A SENS watcher would care because the partnership expands Eversense 365's reach into the iLet Bionic Pancreas user community, potentially broadening its market for its implantable CGM technology.

Senseonics To Participate in Upcoming Institutional Investor Conferences

GlobeNewsWire · 10 Sept 2026neutral

Senseonics Holdings announced it will participate in two upcoming institutional investor conferences. The company is focused on developing long-term, implantable continuous glucose monitoring systems for people with diabetes.

Why it matters — Conference participation gives SENS watchers a chance to see the company present its CGM technology and business to institutional investors.

Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Senseonics Holdings raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.

Why it matters — A watcher of Senseonics would care because the raised outlook and record organic gross margin signal improved operational and financial performance for the company.

FAQ

Frequently asked questions about SENS stock

What is the SENS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Senseonics Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SENS stock a buy right now?

Of the 8 analysts covering Senseonics Holdings, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Senseonics Holdings, Inc. 31 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SENS?

As at 8 Oct 2026, Senseonics Holdings, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).

Will SENS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +60.8% from the last close, and Ticker Nerd's factor model ranks Senseonics Holdings, Inc. 31 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SENS stock forecast for 2030?

No analyst covering Senseonics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SENS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.

How has SENS stock performed over the past year?

Senseonics Holdings, Inc. returned -2.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Senseonics Holdings, Inc. do?

Senseonics Holdings Inc. is a medical technology company focused on long-term implantable continuous glucose monitoring systems for people with diabetes.

What is the latest news on SENS?

The most recent item we track (Seeking Alpha, 8 Oct 2026): "Senseonics: Eversense 365 Adoption Has To Earn The Valuation". Seeking Alpha rates Senseonics Hold, citing sales growth, improving margins and Eversense 365’s product differentiation alongside adoption and funding risks. Recurring revenue depends on repeat implantations and wider prescriber uptake and insurance approval; high SG&A, dilution and negative free cash flow remain concerns.

Company

About Senseonics Holdings, Inc.

Senseonics Holdings Inc. is a medical technology company focused on long-term implantable continuous glucose monitoring systems for people with diabetes. Its Eversense product line combines a small under-the-skin sensor, a removable smart transmitter, and a mobile app to provide ongoing glucose readings, alerts, and diabetes management support. The company’s current offerings are designed to serve patients and healthcare providers seeking an alternative to traditional short-duration CGM devices, with products used in the United States and international markets. Senseonics Holdings Inc. operates in the diabetes management and implantable medical device segments, where it plays a specialized role in glucose monitoring technology. Headquartered in Germantown, Maryland, the company is known for its focus on durable, wearable-connected monitoring solutions that support day-to-day diabetes care.

CEO Dr. Timothy T. Goodnow Ph.D. · 130 employees · United States · https://www.senseonics.com